3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
12
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Melanoma
2
Glioblastoma
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ulnar Neuropathies
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Prostatic Hyperplasia
1
Peripheral Lung Tumor
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Squamous Lung Cancer
1
Neuroma
1
Multiple Myeloma
1
Mucositis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leiomyoma
1
Keratosis, Actinic
1
Hyperthermia
1
Glioma
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
Therapeutics
×
Clear all
NCT03761901
2020-05-08
REVEAL
AstraZeneca
Completed
141 enrolled